PATENT CLAIM ANALYSIS

Application Number: 15951929
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant follistatin protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.

Claim (Index 39):
The method of  claim 1 , wherein the at least one symptom or feature of DMD is selected from the group consisting of muscle wasting, muscle weakness, muscle fragility, muscle necrosis, muscle fibrosis, joint contracture, skeletal deformation, cardiomyopathy, impaired swallowing, impaired bowel and bladder function, muscle ischemia, cognitive impairment, behavioral dysfunction, socialization impairment, scoliosis, and impaired respiratory function.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 91.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14762373', '15075051', '15081629', '14254560', '12893976']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7887314773741367
- 35 USC 102 Novelty (BERT): 0.6904869546804895
- Combined Prediction Score: 0.778907025104772
- Mean Citation Score: 463.8713
- Max Citation Score: 744.8266
- Similarity Product: 698.108899732828

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test